Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis

被引:17
作者
Vincent, Fabien B. [1 ]
Lin, Emily [1 ]
Sahhar, Joanne [1 ,2 ]
Ngian, Gene-Siew [1 ,2 ]
Kandane-Rathnayake, Rangi [1 ]
Mende, Rachel [1 ]
Hoi, Alberta Y. [1 ]
Morand, Eric F. [1 ,2 ]
Lang, Tali [1 ,3 ]
Harris, James [1 ]
机构
[1] Monash Univ, Monash Hlth, Sch Clin Sci, Ctr Inflammatory Dis, Clayton, Vic, Australia
[2] Monash Hlth, Dept Rheumatol, Clayton, Vic, Australia
[3] Cabrini Inst, Szalmuk Family Dept Med Oncol, Malvern, Vic 3144, Australia
基金
英国医学研究理事会;
关键词
biomarker; cytokine; systemic lupus erythematosus (SLE); systemic sclerosis; MIF; EXPRESSION; CYTOKINE; ASSOCIATION; DISEASE; TRIALS; GENE;
D O I
10.1002/cti2.1042
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives. Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT), members of the same cytokine superfamily, are linked to the pathogenesis of a number of inflammatory diseases. The aim of this study was to investigate their clinical relevance in systemic sclerosis (SSc). Methods. Serum MIF and DDT were quantified in 105 SSc patients by ELISA and levels compared to healthy controls (HC) (47) and patients with systemic lupus erythematosus (SLE) (184). Clinical parameters included organ involvement, serum laboratory markers and results of pulmonary function tests, and overall disease activity assessed using the European Scleroderma Trials and Research group (EUSTAR) activity index. Results. There was no significant difference in serum DDT concentrations between patients with SSc and HC. However, serum MIF was significantly increased in SSc compared to both HC and SLE cohorts. Serum MIF was increased in SSc patients with low forced vital capacity (FVC) and was also associated with the use of angiotensin II receptor blockers and beta blockers in SSc, confirmed after adjusting for the presence of systemic hypertension and low FVC. Serum DDT was significantly higher in SSc patients with low FEV1 and negatively correlated with EUSTAR score, particularly in patients with limited disease. Conclusion. Although not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in HC and SLE patients, suggesting a fundamental role for MIF in SSc. DDT, while closely related to MIF, did not show a similar expression profile, suggesting functional differences between these molecules.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Levels of the macrophage migration inhibitory factor and polymorphisms in systemic lupus erythematosus: a meta-analysis
    Sam, Napoleon Bellua
    Guan, Shi-Yang
    Wang, Peng
    Li, Xiao-Mei
    Wang, De-Guang
    Pan, Hai-Feng
    Ye, Dong-Qing
    ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (05) : 1232 - 1240
  • [42] Elevated Serum Macrophage Migration Inhibitory Factor Levels in Post-operative Biliary Atresia
    Nattee, Papit
    Honsawek, Sittisak
    Chongsrisawat, Voranush
    Vejchapipat, Paisarn
    Thamboonlers, Apiradee
    Poovorawan, Yong
    ASIAN JOURNAL OF SURGERY, 2009, 32 (02) : 109 - 113
  • [43] Novel Anti-inflammatory Activity of Epoxyazadiradione against Macrophage Migration Inhibitory Factor INHIBITION OF TAUTOMERASE AND PROINFLAMMATORY ACTIVITIES OF MACROPHAGE MIGRATION INHIBITORY FACTOR
    Alam, Athar
    Haldar, Saikat
    Thulasiram, Hirekodathakallu V.
    Kumar, Rahul
    Goyal, Manish
    Iqbal, Mohd Shameel
    Pal, Chinmay
    Dey, Sumanta
    Bindu, Samik
    Sarkar, Souvik
    Pal, Uttam
    Maiti, Nakul C.
    Bandyopadhyay, Uday
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (29) : 24844 - 24861
  • [44] D-dopachrome tautomerase activates COX2/PGE2 pathway of astrocytes to mediate inflammation following spinal cord injury
    Ji, Huiyuan
    Zhang, Yuxin
    Chen, Chen
    Li, Hui
    He, Bingqiang
    Yang, Ting
    Sun, Chunshuai
    Hao, Huifei
    Zhang, Xingyuan
    Wang, Yingjie
    Zhou, Yue
    Zhu, Zhenjie
    Hu, Yuming
    Li, Aihong
    Guo, Aisong
    Wang, Yongjun
    JOURNAL OF NEUROINFLAMMATION, 2021, 18 (01)
  • [45] Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma
    Soumoy, Laura
    Kindt, Nadege
    Ghanem, Ghanem
    Saussez, Sven
    Journe, Fabrice
    CANCERS, 2019, 11 (04)
  • [46] Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
    Vincent, Fabien B.
    Slavin, Laura
    Hoi, Alberta Y.
    Kitching, Arthur Richard
    Mackay, Fabienne
    Harris, James
    Kandane-Rathnayake, Rangi
    Morand, Eric F.
    LUPUS SCIENCE & MEDICINE, 2018, 5 (01):
  • [47] Serum macrophage migration inhibitory factor in the prediction of preterm delivery
    Pearce, Brad D.
    Garvin, Sicily E.
    Grove, Jakob
    Bonney, Elizabeth A.
    Dudley, Donald J.
    Schendel, Diana E.
    Thorsen, Poul
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008, 199 (01) : 46.e1 - 46.e6
  • [48] Macrophage Migration Inhibitory Factor in Major Depressive Disorder: A Multilevel Pilot Study
    Swoboda, Caroline
    Deloch, Lena
    von Zimmermann, Claudia
    Richter-Schmidinger, Tanja
    Lenz, Bernd
    Kornhuber, Johannes
    Muehle, Christiane
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [49] Assessment of macrophage migration inhibitory factor in humans: protocol for accurate and reproducible levels
    Sobierajski, Julia
    Hendgen-Cotta, Ulrike B.
    Luedike, Peter
    Stock, Pia
    Rammos, Christos
    Meyer, Christian
    Kraemer, Sandra
    Stoppe, Christian
    Bernhagen, Juergen
    Kelm, Malte
    Rassaf, Tienush
    FREE RADICAL BIOLOGY AND MEDICINE, 2013, 63 : 236 - 242
  • [50] Macrophage migration inhibitory factor
    Lolis, E
    Bucala, R
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (02) : 153 - 164